Sodium Sulfacetamide 9.8% and Sulfur 4.8% Cleanser

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name: Sodium Sulfacetamide 9.8% and Sulfur 4.8% Cleanser
Generic name: SULFACETAMIDE SODIUM, SULFUR
Manufacturer: KMM Pharmaceuticals, LLC
Product type: HUMAN PRESCRIPTION DRUG
SPL set ID: db857027-0175-e452-e053-2995a90a4df5
SPL ID: db857027-0176-e452-e053-2995a90a4df5
Version: 1
Effective date: 2022-03-31
Source export date: 2026-09-28
Source partition: 8
Source file: https://download.open.fda.gov/drug/label/drug-label-0008-of-0014.json.zip
Source object key: raw/openfda/drug-label/2026-09-28/ae3816359e336a5de4f44607730a3d12ceb61ffa012a132189ceda22541b38ee/drug-label-0008-of-0014.json.zip
Source manifest SHA-256: cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
Import run: 20260929T050834Z
Imported at: 2026-09-29 05:55:51

Harmonized routes table
Harmonized routes
TOPICAL

Harmonized identifier links#

Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.

Harmonized identifiers page 1 of 1 · 11 matching rows.

Type, Scope, Identifier table
Type	Scope	Identifier	Source field
brand name		Sodium Sulfacetamide 9.8% and Sulfur 4.8% Cleanser	openfda.brand_name
generic name		SULFACETAMIDE SODIUM, SULFUR	openfda.generic_name
manufacturer name		KMM Pharmaceuticals, LLC	openfda.manufacturer_name
ndc	package	52187-546-10	openfda.package_ndc
ndc	product	52187-546	openfda.product_ndc
ndc11	package	52187054610	derived:openfda.package_ndc
rxcui		1494169	openfda.rxcui
spl id		db857027-0176-e452-e053-2995a90a4df5	id
spl set id		db857027-0175-e452-e053-2995a90a4df5	set_id
unii		4NRT660KJQ	openfda.unii
unii		70FD1KFU70	openfda.unii

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

WARNINGS: Sulfonamides are known to cause Stevens-Johnson syndrome in hypersensitive individuals. Stevens-Johnson syndrome also has been reported following the use of sodium sulfacetamide topically. Cases of drug-induced systemic lupus erythematosus from topical sulfacetamide also have been reported. In one of these cases, there was a fatal outcome. KEEP OUT OF THE REACH OF CHILDREN.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 1 matching rows.

adverse reactions

ADVERSE REACTIONS: Reports of irritation and hypersensitivity to sodium sulfacetamide are uncommon. The following adverse reactions, reported after administration of sterile ophthalmic sodium sulfacetamide, are noteworthy: instances of Stevens-Johnson syndrome and instances of local hypersensitivity which progressed to a syndrome resembling systemic lupus erythematosus; in one case a fatal outcome was reported (see WARNINGS).

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.